Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; Department of Anesthesiology, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
EBioMedicine. 2024 May;103:105143. doi: 10.1016/j.ebiom.2024.105143. Epub 2024 Apr 30.
Argon (Ar) has been proposed as a potential therapeutic agent in multiple clinical conditions, specifically in organ protection. However, conflicting data on pre-clinical models, together with a great variability in Ar administration protocols and outcome assessments, have been reported. The aim of this study was to review evidence on treatment with Ar, with an extensive investigation on its neuroprotective effect, and to summarise all tested administration protocols.
Using the PubMed database, all existing pre-clinical and clinical studies on the treatment with Ar were systematically reviewed (registration: https://doi.org/10.17605/OSF.IO/7983D). Study titles and abstracts were screened, extracting data from relevant studies post full-text review. Exclusion criteria included absence of full text and non-English language. Furthermore, meta-analysis was also performed to assess Ar potential as neuroprotectant agent in different clinical conditions: cardiac arrest, traumatic brain injury, ischemic stroke, perinatal hypoxic-ischemic encephalopathy, subarachnoid haemorrhage. Standardised mean differences for neurological, cognitive and locomotor, histological, and physiological measures were evaluated, through appropriate tests, clinical, and laboratory variables. In vivo studies were evaluated for risk of bias using the Systematic Review Center for Laboratory Animal Experimentation tool, while in vitro studies underwent assessment with a tool developed by the Office of Health Assessment and Translation.
The systematic review detected 60 experimental studies (16 in vitro, 7 ex vivo, 31 in vivo, 6 with both in vitro and in vivo) investigating the role of Ar. Only one clinical study was found. Data from six in vitro and nineteen in vivo studies were included in the meta-analyses. In pre-clinical models, Ar administration resulted in improved neurological, cognitive and locomotor, and histological outcomes without any change in physiological parameters (i.e., absence of adverse events).
This systematic review and meta-analysis based on experimental studies supports the neuroprotective effect of Ar, thus providing a rationale for potential translation of Ar treatment in humans. Despite adherence to established guidelines and methodologies, limitations in data availability prevented further analyses to investigate potential sources of heterogeneity due to study design.
This study was funded in part by Italian Ministry of Health-Current researchIRCCS and by Ministero della Salute Italiano, Ricerca Finalizzata, project no. RF 2019-12371416.
氩(Ar)已被提议作为多种临床病症的潜在治疗药物,特别是在器官保护方面。然而,临床前模型中的相互矛盾的数据,以及 Ar 给药方案和结果评估的极大变异性,已经被报道。本研究的目的是综述关于 Ar 治疗的证据,对其神经保护作用进行广泛研究,并总结所有经过测试的给药方案。
使用 PubMed 数据库,系统地检索了所有关于 Ar 治疗的现有临床前和临床研究(注册:https://doi.org/10.17605/OSF.IO/7983D)。筛选研究标题和摘要,从相关研究的全文审查中提取数据。排除标准包括缺乏全文和非英语语言。此外,还进行了荟萃分析,以评估 Ar 在不同临床情况下作为神经保护剂的潜力:心脏骤停、创伤性脑损伤、缺血性中风、围产期缺氧缺血性脑病、蛛网膜下腔出血。通过适当的测试、临床和实验室变量,评估了神经、认知和运动、组织学和生理学测量的标准化均数差异。使用系统评价实验室动物实验中心的工具评估体内研究的偏倚风险,而体外研究则使用健康评估和翻译办公室开发的工具进行评估。
系统综述检测到 60 项实验研究(16 项体外、7 项离体、31 项体内、6 项既有体外又有体内),研究了 Ar 的作用。仅发现一项临床研究。荟萃分析纳入了六项体外和十九项体内研究的数据。在临床前模型中,Ar 给药可改善神经、认知和运动以及组织学结果,而对生理学参数没有任何改变(即没有不良事件)。
本系统综述和基于实验研究的荟萃分析支持 Ar 的神经保护作用,从而为 Ar 治疗在人类中的潜在转化提供了依据。尽管遵循了既定的指南和方法,但由于研究设计,数据可用性的限制使得无法进一步分析以调查潜在的异质性来源。
本研究部分由意大利卫生部-当前研究 IRCCS 和意大利卫生部,研究资助,项目编号 RF 2019-12371416 资助。